The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the growing shift of Big Pharma toward non-traditional psychiatric treatments, Eli Lilly has announced its entry into the psychedelics market by acquiring Atai Beckley. According to reports, the deal is valued at $2.8 billion, aiming to bolster the company's innovative pipeline. The acquisition specifically targets the development of a novel depression drug based on a DMT-like compound known for its potent psychological effects.
This strategic maneuver comes as the biotech sector sees surging interest in psychedelic therapies, fueled by the commercial validation of treatments like Johnson & Johnson's Spravato. In comparison to peers, Eli Lilly is positioning itself to compete with firms such as Compass Pathways, which is also developing psilocybin-based therapies. Per market data, LLY shares have been trading at premium levels, reflecting investor confidence in the company's expansion from obesity treatments into mental health.
Regarding market performance, LLY stock stood at $1170.54 at close July 16, 2026, with a daily range between $1141.2 and $1189.07. Traders are now watching for clinical trial timelines for the new DMT-based candidate, especially as the market awaits the U.S. Monetary Policy Report on July 10, 2026, which could influence risk appetite across the high-growth biotech sector.